DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting

Information source: Hamad Medical Corporation
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Gastroenteritis

Intervention: Ondansetron with1:1 ORA - sweet. (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Hamad Medical Corporation

Official(s) and/or principal investigator(s):
Khalid Al-Ansari, MD, FRCPC, FAAP, Study Chair, Affiliation: Hamad Medical Corporation, Doha - Qatar

Summary

The purpose of this study is to give children with gastroenteritis with persistent vomiting flavored intravenous ondansetron orally. The investigators test the palatability of the drug and check the serum level of ondansetron at 4 hours .

Clinical Details

Official title: Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: ondansetron serum level.

Secondary outcome: palatability score of the drug.score 3/5( not sure to like very much ).

Detailed description: This is a prospective pilot study for children,3-8 years of age presented to the Pediatric Emergency Department in the state of Qatar between September 2014 and January 2015, with acute gastroenteritis with mild to moderate dehydration, more than 2 episodes of vomiting in the last 24 hours, and who had failed oral rehydration trial in the department as per the department oral hydration protocol. Acute gastroenteritis was defined as diarrhea and vomiting for less than a week period. Hydration level was assessed for all patients on arrival, and eligible patients were enrolled after obtaining an informed written consent. Enrolled patients received intravenous ondansetron form orally after being flavored 1: 1 with ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight. Palatability was evaluated by the primary investigator within one minute fom drug administration applying taste scores for children and recorded according to a specific scoring system. All patients were kept nil per oral for 30 minutes and then oral rehydration trial was started as per the department rehydration protocol. If the drug was vomited within 30 min of administration, a similar second dose was given. Blood level for ondansetron was collected 4 hours after the successful drug administration and was sent to the department laboratory within 5 min. Patients were sent home when they were ready for discharge as per the treating physician discretion. All patients were followed by a telephone call after 24 hours to assess the safety and efficacy of the orally taken ondansetron.

Eligibility

Minimum age: 3 Years. Maximum age: 8 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- children 3-8 years of age.

- acute simple gastroenteritis with mild to moderate dehydration.

- more than 2 episodes of vomiting in 24 hours period.

Exclusion Criteria:

- known hypersensitivity to ondansetron.

- seizure disorder.

- chronic liver or kidney diseases.

- on any chronic medication.

Locations and Contacts

Additional Information

Related publications:

Freedman SB, Adler M, Seshadri R, Powell EC. Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med. 2006 Apr 20;354(16):1698-705.

DeCamp LR, Byerley JS, Doshi N, Steiner MJ. Use of antiemetic agents in acute gastroenteritis: a systematic review and meta-analysis. Arch Pediatr Adolesc Med. 2008 Sep;162(9):858-65. doi: 10.1001/archpedi.162.9.858. Review.

Sturm JJ, Pierzchala A, Simon HK, Hirsh DA. Ondansetron use in the pediatric emergency room for diagnoses other than acute gastroenteritis. Pediatr Emerg Care. 2012 Mar;28(3):247-50. doi: 10.1097/PEC.0b013e3182494d87.

Angelilli ML, Toscani M, Matsui DM, Rieder MJ. Palatability of oral antibiotics among children in an urban primary care center. Arch Pediatr Adolesc Med. 2000 Mar;154(3):267-70.

Starting date: September 2014
Last updated: June 14, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017